The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects
Ilaria Vicenti, Francesca Gatti, Renzo Scaggiante, Adele Boccuto, Daniela Zago, Monica Basso, Filippo Dragoni, Saverio Giuseppe Parisi, Maurizio Zazzi
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Neutralizing antibodyVirologyCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakAntibody responseMedicineAntibodyImmunologyInfectious disease (medical specialty)OutbreakVirusDiseaseInternal medicineSARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesViral gastroenteritis research and epidemiology